SCHEMBL23243299

SCHEMBL23243299

CC(C)(C(=O)O)c1ncc(Cl)cc1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 2/20 0.39
MAP4K4 O95819 3/20 0.37
HCAR2 Q8TDS4 1/20 0.33
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
AKR1C3 P42330 1/20 0.33
AKR1C2 P52895 1/20 0.33
CCR9 P51686 1/20 0.33
MAPT P10636 2/20 0.31
MCL1 Q07820 1/20 0.31
MEN1 O00255 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C19 P33261 1/20 0.31
KMT2A Q03164 1/20 0.31
PPARA Q07869 1/20 0.31
EGLN1 Q9GZT9 1/20 0.31
SORT1 Q99523 1/20 0.31
NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23243126 0.87 PLAU (0.39) PLAUHCAR2LMNAL3MBTL1CCR9
SCHEMBL20249967 0.83 MAP4K4 (0.39) MAP4K4HCAR2LMNAL3MBTL1AKR1C3
SCHEMBL23243197 0.83 CNR2 (0.37) PLAUMEN1CYP2C19KMT2APTK2
SCHEMBL29261734 0.81 PLAU (0.36) PLAUHCAR2LMNAL3MBTL1CCR9
SCHEMBL21718409 0.78 PLAU (0.42) PLAULMNAL3MBTL1MEN1KMT2A
SCHEMBL23050836 0.72 PLAU (0.38) PLAU
SCHEMBL10671281 0.71 LMNA (0.41) PLAUMAP4K4HCAR2LMNAL3MBTL1
SCHEMBL2260139 0.71 PLAU (0.42) PLAUL3MBTL1HTTHSD17B10
SCHEMBL31445520 0.70 AGBL2 (0.38) MAP4K4HCAR2AKR1C3AKR1C2PPARA
SCHEMBL16634631 0.69 PLAU (0.44) PLAUHCAR2LMNAL3MBTL1MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4371987-B9 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS GILEAD SCIENCES INC (US) 2025-11-26 EP disclosed
EP-4371987-B1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS GILEAD SCIENCES INC (US) 2025-09-17 EP disclosed
US-12258346-B2 Substituted 6-azabenzimidazole compounds GILEAD SCIENCES, INC. (US) 2025-03-25 US disclosed
US-20240287061-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS GILEAD SCIENCES, INC. 2024-08-29 US disclosed
CN-113227089-B Substituted 6-azabenzimidazole compounds as HPK1 inhibitors 吉利德科学公司 2024-07-05 CN disclosed
EP-4371987-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS Gilead Sciences, Inc. (US) 2024-05-22 EP disclosed
US-11897878-B2 Substituted 6-azabenzimidazole compounds GILEAD SCIENCES, INC. (US) 2024-02-13 US disclosed
EP-3873903-B1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS GILEAD SCIENCES INC (US) 2024-01-24 EP disclosed
EP-3873903-B1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS GILEAD SCIENCES INC (US) 2024-01-24 EP disclosed
US-20220213091-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS GILEAD SCIENCES, INC. 2022-07-07 US disclosed
US-20220213091-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS GILEAD SCIENCES, INC. 2022-07-07 US disclosed
US-11203591-B2 Substituted 6-azabenzimidazole compounds GILEAD SCIENCES, INC. (US) 2021-12-21 US disclosed
US-11203591-B2 Substituted 6-azabenzimidazole compounds GILEAD SCIENCES, INC. (US) 2021-12-21 US disclosed
EP-3873903-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS GILEAD SCIENCES, INC. (US) 2021-09-08 EP disclosed
CN-113227089-A Substituted 6-azabenzimidazole compounds as HPK1 inhibitors 吉利德科学公司 2021-08-06 CN disclosed
US-20210115037-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS GILEAD SCIENCES, INC. 2021-04-22 US disclosed
US-20210115037-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS GILEAD SCIENCES, INC. 2021-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287061-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS CDK6, HIPK1, DCK PLAU 3694/4885MAP4K4 392/4885HCAR2 2568/4885
US-12258346-B2 Substituted 6-azabenzimidazole compounds CDK6, HIPK1, DCK PLAU 3694/4885MAP4K4 392/4885HCAR2 2568/4885
US-20210115037-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS CDK6, HIPK1, DCK PLAU 3694/4885MAP4K4 392/4885HCAR2 2568/4885
US-11203591-B2 Substituted 6-azabenzimidazole compounds CDK6, HIPK1, DCK PLAU 3694/4885MAP4K4 392/4885HCAR2 2568/4885
US-20220213091-A1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS CDK6, HIPK1, DCK PLAU 3694/4885MAP4K4 392/4885HCAR2 2568/4885
US-11897878-B2 Substituted 6-azabenzimidazole compounds CDK6, HIPK1, DCK PLAU 3694/4885MAP4K4 392/4885HCAR2 2568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.